 Xeris Biopharma Holdings Inc NASDAQ: XERS has reaffirmed its preliminary 2021 pro forma sales at a high-end of 76 million - 80 million guidance, approximately 55 growth from 2020. The company held year-end 2021 preliminary cash, cash equivalents, and investments of approximately 102 million. 